Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.340
-0.010 (-0.74%)
At close: Jun 3, 2025, 4:00 PM
1.320
-0.020 (-1.49%)
After-hours: Jun 3, 2025, 7:09 PM EDT
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$670,000
Market Cap
25.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CMMB News
- 16 hours ago - Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis - GlobeNewsWire
- 19 days ago - Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 - GlobeNewsWire
- 5 weeks ago - Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases - GlobeNewsWire
- 6 weeks ago - Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences - GlobeNewsWire
- 7 weeks ago - Chemomab Announces New Medical and Clinical Appointments - GlobeNewsWire
- 2 months ago - Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease - Benzinga
- 2 months ago - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers - GlobeNewsWire